Technology Inc. (Palo Alto, Calif.) Pfizer Inc. (New York) ND Deal for rights to use Open Monoclonal's OmniRat platform for antibody research and development Financial terms were not disclosed 9/19/12 Open Monoclonal Technology Inc. (Palo Alto, Calif.) WuXi PharmaTech Inc. (Shanghai, China) ND Agreement to use its OmniRat technology to develop therapeutic antibody candidates for commercialization by WuXi's customers Financial terms were not disclosed 9/5/12 Scynexis Inc. (Research Triangle Park
Senesco Technologies Inc., of Bridgewater, N.J., said its shares will be quoted under the ticker symbol "SNTI" on the Over-the-Counter Bulletin Board as of Nov. 21
financial terms were not disclosed 9/28/12 OCTOBER Gentium SpA (Villa Guardia, Italy) Biologix FZCo (Dubai, United Arab Emirates) ND Exclusive distribution of Defibrotide in the Middle East and North Africa Under terms of the 10-year agreement, Biologix will handle named-patient requests, obtain price and reimbursement approvals in those regions and be responsible for sales, marketing and local media affairs 10/5/12 Pfenex Inc. (San Diego) Althea Technologies Inc. (San Diego) ND Contract for the
Total Value in 2012: $6,312.15M* Number of Deals in 2012: 216 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date SEPTEMBER Astex Pharmaceuticals Inc. (Dublin, Calif.) Cancer Research Technology Ltd. (Cambridge, UK) and the Institute of Cancer Research (London) ND Initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in blood cancer with high unmet medical need The collaboration will combine Astex's fragment
Senesco Technologies Inc., of Bridgewater, N.J., was notified that the New York Stock Exchange will delist its stock (NYSE:SNT) prior to the opening of trading on Nov. 21 , due to its inability to meet the exchange's continued listing requirements
formerly EB-1010 Major depressive disorder Completed enrollment in the Phase IIb/IIIa study 10/12/12 Grupo Zeltia (Madrid, Spain) Tideglusib A GSK-3 inhibitor Mild-to-moderate Alzheimer's disease The primary cognitive endpoint and two of the secondary endpoints were not met in the 26-week ARGO Phase IIb trial 10/12/12 ISTO Technologies Inc. (St. Louis) NuQu Cell-based therapy Pain and disability associated with degenerated spinal discs Started a Phase II trial 10/23/12 Nabi Biopharma-ceuticals
BiOasis Technologies Inc., of Vancouver, British Columbia, entered a research and evaluation agreement with MedImmune Inc., of Gaithersburg, Md., the biologics arm of AstraZeneca plc
Advanced Cell Technology Inc., of Santa Monica, Calif., said it has treated 13 patients thus far in its three ongoing trials for dry age-related macular degeneration and Stargardt's disease using human embryonic stem cell-derived retinal pigment epithelial cells
That is certainly the case for Cranbury, N.J.-based Palatin Technologies Inc., which saw its shares vault 21.4 percent by close of trading Thursday after reporting positive top-line results from its Phase IIb trial on bremelanotide, a synthetic peptide analogue of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone), for the treatment of female sexual dysfunction (FSD
By Peter Winter | BioWorld Today | Friday, November 9, 2012
Senesco Technologies Inc., of Bridgewater, N.J., said it expanded its clinical trial of SNS01-T to include diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) patients
Advanced Cell Technology Inc. (ACT), of Marlborough, Mass., said the independent data and safety monitoring board for its three ongoing trials approved the enrollment and treatment of two additional patients with dry age-related macular degeneration, representing the final patients in the trial's three-patient second cohort
Pfenex Inc., of San Diego, awarded Althea Technologies Inc., also of San Diego, a contract for the cGMP manufacturing of circumsporozoite protein from Plasmodium falciparum, a component of an effective malaria vaccine
ISTO Technologies Inc., of St. Louis, initiated a Phase II trial to further evaluate the efficacy and safety of its NuQu cell-based therapy in treating pain and disability associated with degenerated spinal discs
Technologies Inc. (Bridgewater, N.J.) SNS01-T Designed to selectively trigger apoptosis in B-cell cancers Multiple myeloma First patient was enrolled and dosing has begun in the second cohort of its open-label study 9/14/12 TG Therapeutics Inc. (New York) Ublituximab Third-generation anti-CD20 monoclonal antibody B-cell non-Hodgkin's lymphoma Started a Phase I/II trial 9/6/12 CARDIOVASCULAR & RESPIRATORY Galleon Pharmaceuticals Inc. (Horsham, Pa.) GAL-021 A small molecule Acute respiratory
Althea Technologies Inc., of San Diego, named Rick Hancock president and CEO, Chris Duffy senior vice president of operations and E.J. Brandreth senior vice president of quality and regulatory
Advanced Cell Technology Inc., of Marlborough, Mass., said the data and safety monitoring board (DSMB) authorized the company to move forward with enrollment and treatment of second and third additional patients with Stargardt's macular dystrophy (SMD) in the second patient cohort of its U.S
Advanced Cell Technology Inc., of Marlborough, Mass., said it treated three additional patients in its U.S